Pharmaceuticals firm Hester Biosciences announced Q1FY23 Result : Q1 FY23 Standalone revenues down 14%, Consolidated revenues down 16% Consolidated results also include operations of subsidiaries at Nepal and Tanzania. Hester Nepal has registered 16% growth in domestic revenues, however, there were no tender sales in the current quarter due to delay in tendering by FAO and other multilateral institutions. Hester Tanzania has just started commercial operations and recently received regulatory approvals for four products with two additional products under approval process. Revenues are expected to start in Q2. Result PDF